Yasuni Nakanuma

Dr. Yasuni Nakanuma


Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2017 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
YNYasuni Nakanuma
Yasuni Nakanuma
KJKee‐Taek Jang
Kee‐Taek Jang
NFNoriyoshi Fukushima
Noriyoshi Fukushima
TFToru Furukawa
Toru Furukawa
SHSeung-Mo Hong
Seung-Mo Hong
KKKeiichi Kubota
Keiichi Kubota

18 January 2013 in Cancer
Verified
Journal Article
Open access
PDF file
MHMaylee Hsu
Maylee Hsu
MSMotoko Sasaki
Motoko Sasaki
SISaya Igarashi
Saya Igarashi
YSYasunori Sato
Yasunori Sato
YNYasuni Nakanuma
Yasuni Nakanuma
BACKGROUND: Similar to the pancreatic intraepithelial neoplasia (PanIN)‐pancreatic carcinoma sequence model, intrahepatic cholangiocarcinoma (ICC) also reportedly follows a stepwise carcinogenesis process through the a precursor lesion: biliary intraepithelial neoplasia (BilIN). For this study, the authors investigated the status of v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and GNAS complex locus (GNAS) mutations and tumor protein 53 (p53) overexpression in the stepwise process of cholangiocarcinogenesis.METHODS: Thirty patients with hepatolithiasis were surveyed, and their lesions were categorized as follows: non‐neoplastic large bile duct (LBD) (n = 12), peribiliary gland (PBG) (n = 9), BilIN‐1 (low‐grade dysplasia; n = 12), BilIN‐2 (high‐grade dysplasia; n = 16), and BilIN‐3 (noninvasive or in situ carcinoma; n = 10). KRAS mutation at codons 12 and 13 and GNAS mutations at codons 601 and 602 were analyzed using genomic DNA extracted from isolated lesions by laser capture microdissection. Immunohistochemical expression of p53 also was evaluated in BilIN lesions, ICCs, and extrahepatic cholangiocarcinomas (ExCCs).RESULTS: A prevalence of KRAS mutations was identified in patients with ICC (31.5%), BilIN‐3 (30%), and BilIN‐2 (43.8%) compared with BilIN‐1 (25%). Furthermore, KRAS mutations were detected in LBD lesions (41.7%) and PBG lesions (44.4%), and these mutations were observed with greater frequency in patients who had BilIN with KRAS mutations. GNAS mutations were not identified in any of the ICCs or other lesions examined. The overexpression of p53 was not identified in BilIN lesions and was less frequent in ICCs (18.2%) compared with ExCCs (38.1%) and gallbladder carcinomas (61.5%).CONCLUSIONS: KRAS mutations, which were present in approximately 33% of BilIN lesions, occurred as an early molecular event during the progression of BilIN to ICC, whereas p53 overexpression was identified as a late molecular event. Furthermore, the current results indicted that BilIN also may arise from LBD and PBG lesions in patients who have hepatolithiasis with KRAS mutations. Cancer 2013. © 2013 American Cancer Society.

29 April 2014 in Liver International
Verified
Journal Article
Closed access
PDF file
MSMotoko Sasaki
Motoko Sasaki
HSHirohide Sato
Hirohide Sato
YKYuko Kakuda
Yuko Kakuda
YSYasunori Sato
Yasunori Sato
JCJoon Hyuk Choi
Joon Hyuk Choi
YNYasuni Nakanuma
Yasuni Nakanuma

9 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YNYasuni Nakanuma
Yasuni Nakanuma
KUKatsuhiko Uesaka
Katsuhiko Uesaka
YKYuko Kakuda
Yuko Kakuda
TSTakashi Sugino
Takashi Sugino
Keiichi KubotaKeiichi Kubota
Keiichi Kubota
TTTakuro Terada
Takuro Terada
Intraductal papillary neoplasm of the bile duct (IPNB), a pre-invasive neoplasm of the bile duct, is being established pathologically as a precursor lesion of invasive cholangiocarcinoma (CCA), and at the time of surgical resection, approximately half of IPNBs show stromal invasion (IPNB associated with invasive carcinoma). IPNB can involve any part of the biliary tree. IPNB shows grossly visible, exophytic growth in a dilated bile duct lumen, with histologically villous/papillary neoplastic epithelia with tubular components covering fine fibrovascular stalks. Interestingly, IPNB can be classified into four subtypes (intestinal, gastric, pancreatobiliary and oncocytic), similar to intraductal papillary mucinous neoplasm of the pancreas (IPMN). IPNBs are classified into low-grade and high-grade based on lining epithelial features. The new subclassification of IPNB into types 1 (low-grade dysplasia and high-grade dysplasia with regular architecture) and 2 (high-grade dysplasia with irregular architecture) proposed by the Japan–Korea pathologist group may be useful in the clinical field. The outcome of post-operative IPNBs is more favorable in type 1 than type 2. Recent genetic studies using next-generation sequencing have demonstrated the existence of several groups of mutations of genes: (i) IPNB showing mutations in KRAS, GNAS and RNF43 belonged to type 1, particularly the intestinal subtype, similar to the mutation patterns of IPMN; (ii) IPNB showing mutations in CTNNB1 and lacking mutations in KRAS, GNAS and RNF43 belonged to the pancreatobiliary subtype but differed from IPMN. IPNB showing mutation of TP53, SMAD4 and PIK3CA might reflect complicated and other features characterizing type 2. The recent recognition of IPNBs may facilitate further clinical and basic studies of CCA with respect to the pre-invasive and early invasive stages.

15 November 2019 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YNYasuni Nakanuma
Yasuni Nakanuma
YKYuko Kakuda
Yuko Kakuda
KUKatsuhiko Uesaka
Katsuhiko Uesaka
Yasuni Nakanuma, Yuko Kakuda, and Katsuhiko Uesaka. Gut and Liver 2019;13:617-27. https://doi.org/10.5009/gnl18476

2 November 2013 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MSMotoko Sasaki
Motoko Sasaki
MMMasami Miyakoshi
Masami Miyakoshi
YSYasunori Sato
Yasunori Sato
YNYasuni Nakanuma
Yasuni Nakanuma